T. Rowe Price Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $309M | Buy |
|
|||||
|
2025
Q1 | $299M | Buy |
|
|||||
|
2024
Q4 | $256M | Buy |
|
|||||
|
2024
Q3 | $308M | Sell |
|
|||||
|
2024
Q2 | $394M | Sell |
|
|||||
|
2024
Q1 | $492M | Sell |
|
|||||
|
2023
Q4 | $475M | Buy |
|
|||||
|
2023
Q3 | $463M | Sell |
|
|||||
|
2023
Q2 | $464M | Buy |
|
|||||
|
2023
Q1 | $437M | Buy |
|
|||||
|
2022
Q4 | $408M | Buy |
|
|||||
|
2022
Q3 | $331M | Sell |
|
|||||
|
2022
Q2 | $646M | Sell |
|
|||||
|
2022
Q1 | $662M | Buy |
|
|||||
|
2021
Q4 | $667M | Buy |
|
|||||
|
2021
Q3 | $565M | Buy |
|
|||||
|
2021
Q2 | $584M | Sell |
|
|||||
|
2021
Q1 | $555M | Sell |
|
|||||
|
2020
Q4 | $609M | Sell |
|
|||||
|
2020
Q3 | $666M | Buy |
|
|||||
|
2020
Q2 | $719M | Buy |
|
|||||
|
2020
Q1 | $650M | Buy |
|
|||||
|
2019
Q4 | $717M | Buy |
|
|||||
|
2019
Q3 | $651M | Buy |
|
|||||
|
2019
Q2 | $606M | Sell |
|
|||||
|
2019
Q1 | $705M | Sell |
|
|||||
|
2018
Q4 | $691M | Buy |
|
|||||
|
2018
Q3 | $657M | Sell |
|
|||||
|
2018
Q2 | $672M | Buy |
|
|||||
|
2018
Q1 | $643M | Sell |
|
|||||
|
2017
Q4 | $588M | Sell |
|
|||||
|
2017
Q3 | $678M | Buy |
|
|||||
|
2017
Q2 | $580M | Buy |
|
|||||
|
2017
Q1 | $450M | Buy |
|
|||||
|
2016
Q4 | $400M | Buy |
|
|||||
|
2016
Q3 | $349M | Buy |
|
|||||
|
2016
Q2 | $336M | Buy |
|
|||||
|
2016
Q1 | $282M | Sell |
|
|||||
|
2015
Q4 | $333M | Buy |
|
|||||
|
2015
Q3 | $310M | Buy |
|
|||||
|
2015
Q2 | $259M | Sell |
|
|||||
|
2015
Q1 | $405M | Buy |
|
|||||
|
2014
Q4 | $358M | Buy |
|
|||||
|
2014
Q3 | $383M | Sell |
|
|||||
|
2014
Q2 | $483M | Buy |
|
|||||
|
2014
Q1 | $481M | Buy |
|
|||||
|
2013
Q4 | $441M | Buy |
|
|||||
|
2013
Q3 | $348M | Sell |
|
|||||
|
2013
Q2 | $375M | Buy |
|